4th German-speaking CytoSorb user meeting 2017
The 4th German-speaking CytoSorb user meeting 2017 took place on the eve of the 17th DIVI 2017 in Leipzig. An excellent panel of speakers presented new data and insights on the following topics:
- Sepsis and systemic hyperinflammation with interim evaluation of the CytoSorb registry
- Practical aspects of CytoSorb therapy such as the beginning, end and time of the adsorber change
- Intraoperative use in cardiac surgery
- Other indications such as liver failure, pancreatitis and rhabdomyolysis
The outstanding presentations were followed by a lively panel discussion among the more than 100 attendees, who also used the meeting for an intensive exchange of experiences apart from the lectures.
So far, more than 35,000 individual applications have been performed in more than 500 clinical departments worldwide with CytoSorb therapy.
Cytosorbents Europe GmbH, headquartered in Berlin, is a wholly owned subsidiary of CytoSorbents Corporation of Monmouth Junction, New Jersey, USA, where the CytoSorb product is manufactured. CytoSorb is the company’s flagship product, backed by more than 30 patent families.
Welcome: 6th International CytoSorb Users` Meeting
Subscribe to our newsletter now!
Get access to the CytoSorbents Community Area. The current newsletter contains a direct link to the CytoSorbents Community Area.